{
    "root": "191b4856-1662-a7b8-e063-6394a90a2c56",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pitavastatin",
    "value": "20240523",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM OXIDE",
            "code": "3A3U0GI71G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31794"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "PITAVASTATIN CALCIUM",
            "code": "IYD54XEG3W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_71258"
        }
    ],
    "indications": {
        "text": "pitavastatin tablets indicated adjunct diet reduce low-density lipoprotein cholesterol ( ldl-c ) : adult primary hyperlipidemia . adults pediatric patients aged 8 years older heterozygous familial hypercholesterolemia ( hefh ) .",
        "doid_entities": [
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "take orally daily without food time day ( 2.1 ) . patients requiring high-intensity statin unable achieve ldl-c goal receiving pitavastatin tablets 4 mg daily , prescribe alternative ldl-c-lowering treatment . ( 2.1 ) . assess ldl-c clinically appropriate , early 4 weeks initiation pitavastatin tablets , adjust necessary . ( 2.1 ) . recommended 2 mg 4 mg daily . maximum recommended 4 mg daily . ( 2.2 ) recommended starting patients moderate severe renal impairment end-stage renal disease hemodialysis 1 mg daily . maximum recommended 2 mg daily . ( 2.3 ) full prescribing information pitavastatin tablets modifications due . ( 2.4 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "pitavastatin tablets oral provided white off-white circular biconvex film-coated tablets contain 1 mg , 2 mg , 4 mg pitavastatin . tablet \u201c op \u201d debossed one side code number tablet strength . packaging pitavastatin tablets supplied : 1 mg : white off-white circular biconvex film-coated tablets , debossed logo \u201c op \u201d one side \u201c 57 \u201d side . supplied follows : ndc 0480-3631-98 ; hdpe bottles 90 tablets 2 mg : white off-white circular biconvex film-coated tablets , debossed logo \u201c op \u201d one side \u201c 58 \u201d side . supplied follows : ndc 0480-3632-98 ; hdpe bottles 90 tablets 4 mg : white off-white circular biconvex film-coated tablets , debossed logo \u201c op \u201d one side \u201c 59 \u201d side . supplied follows : ndc 0480-3633-98 ; hdpe bottles 90 tablets storage store 25\u00b0c ( 77\u00b0 f ) , excursions permitted 15\u00b0c-30\u00b0c ( 59\u00b0f-86\u00b0f ) . [ usp controlled room temperature ] . protect light .",
    "adverseReactions": "pitavastatin tablets contraindicated following conditions : concomitant cyclosporine [ ( 7 ) ] . acute liver failure decompensated cirrhosis [ warning ( 5.3 ) ] . hypersensitivity pitavastatin excipients pitavastatin tablets . hypersensitivity including angioedema , rash , pruritus , urticaria reported pitavastatin tablets [ ( 6 ) ] .",
    "indications_original": "Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n                  \n                     Adult with primary hyperlipidemia.\n                     Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).",
    "contraindications_original": "Take orally once daily with or without food at the same time each day ( 2.1 ). For patients requiring a high-intensity statin or are unable to achieve their LDL-C goal receiving pitavastatin tablets 4 mg daily, prescribe alternative LDL-C-lowering treatment. ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiation of pitavastatin tablets, and adjust the dosage if necessary. ( 2.1 ). Recommended dosage is 2 mg to 4 mg once daily. Maximum recommended dosage is 4 mg once daily. ( 2.2 ) Recommended starting dosage for patients with moderate and severe renal impairment and end-stage renal disease on hemodialysis is 1 mg once daily. Maximum recommended dosage is 2 mg once daily. ( 2.3 ) See full prescribing information for pitavastatin tablets dosage modifications due to drug interactions. ( 2.4 )",
    "warningsAndPrecautions_original": "Pitavastatin tablets for oral administration are provided as white to off-white circular biconvex film-coated tablets that contain 1 mg, 2 mg, or 4 mg of pitavastatin. Each tablet has \u201cOP\u201d debossed on one side and a code number specific to the tablet strength on the other.\n                  \n                  \n                     \n                     Packaging\n                     \nPitavastatin tablets are supplied as:\n \n                  \n                     1 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo \u201cOP\u201d on one side and \u201c57\u201d on the other side.\n                  \n                  \u3000Supplied as follows:\n                   \u3000\u3000NDC 0480-3631-98; HDPE bottles of 90 tablets\n                  \n                     2 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo \u201cOP\u201d on one side and \u201c58\u201d on the other side.\n                  \n                  \u3000Supplied as follows:\n                  \u3000\u3000NDC 0480-3632-98; HDPE bottles of 90 tablets\n                  \n                     4 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo \u201cOP\u201d on one side and \u201c59\u201d on the other side.\n                  \n                  \u3000Supplied as follows:\n                  \u3000\u3000NDC 0480-3633-98; HDPE bottles of 90 tablets\n                  \n                  \n                     Storage\n                     \nStore at 25\u00b0C (77\u00b0 F), excursions permitted from 15\u00b0C-30\u00b0C (59\u00b0F-86\u00b0F). [See USP Controlled Room Temperature]. Protect from light.",
    "adverseReactions_original": "Pitavastatin tablets are contraindicated in the following conditions:\n                  \n                     Concomitant use of cyclosporine\n    [see Drug Interactions (\n                        7\n                        )].\n  \n                     Acute liver failure or decompensated cirrhosis \n   [see Warning and Precautions (\n                        5.3\n                        )].\n                     \n                     Hypersensitivity to pitavastatin or any excipients in pitavastatin tablets. Hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin tablets \n   [see Adverse Reactions (\n                        6\n                        )].",
    "drug": [
        {
            "name": "Pitavastatin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32020"
        }
    ]
}